Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial.
Rody A, Karn T, Solbach C, Gaetje R, Munnes M, Kissler S, Ruckhäberle E, Minckwitz GV, Loibl S, Holtrich U, Kaufmann M. Rody A, et al. Among authors: minckwitz gv. Breast. 2007 Jun;16(3):235-40. doi: 10.1016/j.breast.2007.02.006. Epub 2007 Apr 20. Breast. 2007. PMID: 17449250
Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A. Rody A, et al. Zentralbl Gynakol. 2006 Apr;128(2):76-81. doi: 10.1055/s-2006-921508. Zentralbl Gynakol. 2006. PMID: 16673249 Clinical Trial.
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
Huober J, Fasching PA, Hanusch C, Rezai M, Eidtmann H, Kittel K, Hilfrich J, Schwedler K, Blohmer JU, Tesch H, Gerber B, Höß C, Kümmel S, Mau C, Jackisch C, Khandan F, Costa SD, Krabisch P, Loibl S, Nekljudova V, Untch M, Minckwitz Gv. Huober J, et al. Among authors: minckwitz gv. Eur J Cancer. 2013 Jul;49(10):2284-93. doi: 10.1016/j.ejca.2013.02.027. Epub 2013 Mar 27. Eur J Cancer. 2013. PMID: 23541564 Clinical Trial.
Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group.
Thomssen C, Vetter M, Kantelhardt EJ, Meisner C, Schmidt M, Martin PM, Clatot F, Augustin D, Hanf V, Paepke D, Meinerz W, Hoffmann G, Wiest W, Sweep FCGJ, Schmitt M, Jänicke F, Loibl S, Minckwitz GV, Harbeck N; NNBC 3-Europe Study Group. Thomssen C, et al. Among authors: minckwitz gv. Cancers (Basel). 2023 Mar 3;15(5):1580. doi: 10.3390/cancers15051580. Cancers (Basel). 2023. PMID: 36900372 Free PMC article.
Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study.
Bauknecht T, Hefti A, Morack G, Villena-Heinsen C, Wallwiener D, Elling D, Minckwitz GV, Mansouri K, Blatter J, Breitbach GP. Bauknecht T, et al. Among authors: minckwitz gv. Int J Gynecol Cancer. 2003 Mar-Apr;13(2):130-7. doi: 10.1046/j.1525-1438.2003.13039.x. Int J Gynecol Cancer. 2003. PMID: 12657112 Clinical Trial.
State of the art in neoadjuvant therapy of breast cancer.
Minckwitz Gv, Fontanella C. Minckwitz Gv, et al. EJC Suppl. 2013 Sep;11(2):284-5. doi: 10.1016/j.ejcsup.2013.07.043. EJC Suppl. 2013. PMID: 26217146 Free PMC article. Review. No abstract available.